Wt1 Peptide Vaccine, one of the most Promising Cancer Vaccines: Its Present Status and the Future Prospects (2010)

ImmunotherapyVol. 2, No. 5 EditorialFree AccessWT1 peptide vaccine, one of the most promising cancer vaccines: its present status and the future prospectsYoshihiro Oka & Haruo SugiyamaYoshihiro Oka† Author for correspondenceDepartment of Respiratory Medicine, Allergy & Rheumatic Diseases, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan. & Haruo SugiyamaDepartment of Functional Diagnostic Science, Graduate School of Medicine, Osaka University, Osaka, JapanPublished Online:29 Sep 2010https://doi.org/10.2217/imt.10.58AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit Keywords: cancer antigenpeptide vaccineWT1WT1 has features appropriate for a cancer antigenIt has been demonstrated that T-cell-mediated immunity has the power to control cancer. An example is hematopoietic stem cell transplantation (HSCT), which confers a powerful T-cell-mediated graft-versus-leukemia (GVL) or graft-versus-tumor (GVT) effect. The undisputed effect of GVL/GVT led to the idea that autologous T lymphocytes, as well as donor T lymphocytes, may eradicate cancer cells, provided that cytotoxic T lymphocytes (CTLs) that recognize cancer cell-derived antigens, so-called 'cancer antigens', are appropriately activated.To date, hundreds of cancer antigens have been identified, one of which is the Wilms tumor gene (WT1) product, which has two features appropriate for a cancer antigen [1]. First, WT1 gene possesses oncogenic functions. This is a theoretical advantage for using its product, the WT1 protein, as a target antigen, because WT1 expression is thought to be essential for maintaining the transformed characteristics of cancer cells, and tumor escape from immune surveillance as a result of its downmodulation is unlikely to occur [1,2]. Second, wild-type WT1 is expressed in many kinds of hematological and solid malignancies, which indicates that WT1-targeting immunotherapy can be used for a variety of malignancies [1,2]. On the basis of these features and other findings described later, WT1 has been ranked as the most promising cancer antigen in a recent prestigious paper [3]. In addition, leukemia stem cells have been shown to express WT1, which supports the superiority of WT1 as a cancer antigen, because it indicates the possibility that WT1-directed immunotherapy can target cancer stem cells [4].WT1-directed immune response is detected in patients with high tumor burden & in patients after HSCTWhen tumor cells are damaged spontaneously or by treatment, they release WT1 protein, which elicits WT1-specific humoral and cellular immunity [2]. The former is the production of WT1-specific antibodies and the latter is the induction and/or activation of WT1-specific CTLs or helper T lymphocytes. A series of investigations has demonstrated the high immunogenecity of WT1 protein. As for humoral immunity, it was demonstrated that a considerable proportion of leukemia patients responded to the leukemia cell-derived WT1 protein and produced IgM- and IgG-type WT1 antibodies, indicating that not only WT1-specific B cells but also T cells that induce immunoglobulin class-switching of WT1 antibodies were activated in them [5]. Furthermore, it was recently found that the disease-free survival rate of non-small-cell lung cancer (NSCLC) patients with high titers of WT1 IgG antibodies was better than that of NSCLC patients with low titers, which suggests that WT1 plays an important role as a target antigen in tumor immunity for NSCLC [6]. It was also shown that high values of anti-WT1 antibody constitute predictors of longer survival for myelodysplastic syndrome (MDS) patients, which is consistent with the above result regarding NSCLC [7]. Several investigations have also provided direct evidence of spontaneous elicitation of WT1-specific CD8+ CTL response, which is a principal effector response in tumor immunity [1,8]. These findings suggest that WT1-specific immune response for the elimination of tumors is induced in many cancer patients, although the induced response is not strong enough to control the tumor growth or is diminished by tolerance mechanisms. In other words, if the spontaneous WT1-specific CD8+ CTL response can be suitably boosted, the enhanced response may result in a successful attack on tumor cells. In addition to spontaneous elicitation of WT1-specific CTL response in cancer patients, this response seems to be involved in GVL or GVT effect after HSCT [9]. This finding suggests that boosting the WT1-specific CTL response after HSCT may enhance GVL or GVT effect, thereby leading to a decrease in relapse rate after HSCT. If this can be confirmed, HSCT followed by WT1-targeting immunotherapy may become a standard therapy for patients with a high risk of relapse following treatment with HSCT alone.Various kinds of malignancies were successfully treated with WT1 peptide vaccine. These reports are being accumulatedTheoretically, in vivo activation of naturally occurring WT1-specific CTLs by vaccination with WT1 CTL peptide should damage tumor cells [2]. This hypothesis prompted us to start clinical trials for WT1 peptide vaccination [10,11]. Our report, published in 2003, on two MDS patients who received WT1 peptide vaccination is the first to describe its clinical application [10]. Successful reduction of leukemic blast and/or WT1 expression levels that reflect tumor burden, as well as leukocytopenia, was induced. It is considered that most of the normal-appearing blood cells in these MDS patients are derived from WT1-expressing transformed hematopoietic stem or progenitor cells, which were attacked by WT1-specific CTLs activated by the vaccination. Subsequently, other groups also reported clinical responses in MDS patients [1,12,13]. As for hematological malignancies other than MDS, WT1 vaccination-induced clinical responses were reported for acute myeloid leukemia and multiple myeloma [1,11,13]. A recent investigation reported an interesting case of acute myeloid leukemia, for whom WT1 peptide vaccination resulted in the disappearance of trisomy 8, a molecular marker, and an improvement of anemia [13]. It is considered that WT1 peptide vaccination eradicated the abnormal clones, which then led to the recovery of normal hematopoiesis. WT1 vaccination-associated disappearance of a molecular marker other than WT1 expression level should be considered robust evidence for the vaccine's therapeutic potential. A chronic myelogenous leukemia patient successfully treated with WT1 peptide vaccine in combination with imatinib, a molecular-target-based drug, was also reported [14].WT1 peptide vaccination has been applied to solid cancers. To date, clinical responses in patients with breast cancer, lung cancer, renal cancer, ovarian cancer and glioblastoma have been reported [1,2,11,15,16]. Successful WT1 peptide vaccination for childhood malignancies has also been reported [17].One criticism of cancer vaccines is that response rates induced by these vaccines, that is, percentage of complete response plus partial response, are very low compared with those induced by chemotherapy. However, the action mechanisms of chemotherapy and cancer vaccine are quite different [1,2]. The former attacks tumor cells directly, while the latter activates cancer antigen-directed immune system, which then attacks tumor cells. Furthermore, cancer vaccination is not as rapid-acting as chemotherapy. Such difference could explain the relatively low response rate of cancer vaccine. However, since cancer vaccine-associated systemic side effects are usually very mild, the vaccination can be repeated, which may result in disease stabilization or tumor shrinkage after the initial growth (late response), or long-term disease stabilization with good quality of life. In fact, there have been reports of patients with such clinical course [1,15,16,18].We should develop ways to further enhance WT1 peptide vaccine's efficacyHere, we summarize the prospects for WT1 peptide vaccine, based on the present situation. Identification of WT1 CTL epitopes, performed by us and other groups, was first published in 2000 [1,19–22]. Subsequently, accumulating evidence has demonstrated that vaccination of patients with a 'single kind' of WT1 peptide can induce WT1-specific immunological responses and the associated clinical responses, thus clearly indicating that WT1 peptide vaccination has a therapeutic potential. As a next step, we should develop ways to enhance this vaccine's therapeutic efficacy [1,2]. From an immunological point of view, the following possibilities merit consideration [1,2]: ▪ Vaccination with multiple kinds of WT1 CTL peptides;▪ Covaccination with WT1 helper peptides;▪ Using a stronger adjuvant locally injected together with WT1 peptide;▪ Using systemic cytokines;▪ Combined use with anticostimulatory molecule antibodies.As previously mentioned, successful results have been reported for WT1 peptide vaccination in combination with imatinib [14]. Previously, successful treatment of chronic myelogenous leukemia patients with a combination of multiple peptides targeting BCR–ABL fusion protein and imatinib had been reported [23]. These findings suggest that administration of a combination of a molecular target-based drug and cancer vaccine constitutes a promising treatment strategy. The use of a combination of WT1 peptide vaccine and chemotherapy drugs is also interesting, since it was reported that the removal of regulatory T cells or blockade of their function by coadministration of cyclophosphamide or gemcitabine-containing chemotherapy may improve the efficacy of peptide vaccine. Certain types of molecular-target-based drugs and chemotherapy drugs should therefore constitute promising partners for WT1 peptide vaccine [1,2].In order to enhance the usefulness of WT1 peptide vaccine, it is important to identify suitable target patients for the vaccine. For early-phase clinical trials, patients with advanced-stage disease are usually recruited. Next, we should proceed to clinical trials in an adjuvant setting, in which we treat patients with minimal residual disease (MRD) after operation, chemotherapy, radiation or HSCT [1,2,24]. In these patients, the effector:target ratio is high and an immunosuppressive environment induced by a large tumor burden is unlikely to occur, which leads us to expect that immunotherapy should be more effective for patients with MRD than for those with a high tumor burden. Treatment of MRD patients with WT1 peptide vaccine may not be popular among clinical oncologists, because it is difficult to observe short-term effects. However, the importance of WT1 peptide-based clinical trials in the adjuvant setting warrants recognition.We therefore need to establish the optimal timing and method for WT1 peptide vaccination, that is, for patients at advanced stages or with MRD and with the vaccine alone or in combination with other treatments. Identification of immunological markers that predict the vaccination-associated clinical response, which can target the most suitable patients more precisely, is also useful. If these things can be achieved, WT1 peptide vaccine can be expected to play an important role in the treatment of malignancies.Financial & competing interests disclosureThis work is supported by a Grant-in-Aid from the Ministry of Education, Science, Sports, Culture and Technology, Japan. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. The authors used Nakamura Systems Colt. (Ikeda City, Japan) for English writing assistance in the production of this manuscript.Bibliography1 Oka Y, Tsuboi A, Oji Y et al.: WT1 peptide vaccine for the treatment of cancer. Curr. Opin. Immunol.20(2),211–220 (2008).Crossref, Medline, CAS, Google Scholar2 Oka Y, Tsuboi A, Fujiki F et al.: "Cancer antigen WT1 protein-derived peptide"-based immunotherapy for malignancies: successful induction of anti-cancer effect by vaccination with a single kind of WT1 peptide. Curr. Med. Chem.15(29),3052–3061 (2008).Crossref, Medline, CAS, Google Scholar3 Cheever MA, Allison JP, Ferris AS et al.: The prioritization of cancer antigens: a National Cancer Institute pilot project for the acceleration of translational research. Clin. Cancer Res.15(17),5323–5337 (2009).Crossref, Medline, Google Scholar4 Saito Y, Kitamura H, Hijikata A et al.: Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci. Transl. Med.2,17RA9 (2010).Crossref, Medline, Google Scholar5 Elisseeva OA, Oka Y, Tsuboi A et al.: Humoral immune responses against Wilms' tumor gene WT1 product in patients with hematopoietic malignancies. Blood99(9),3272–3279 (2002).Crossref, Medline, CAS, Google Scholar6 Oji Y, Kitamura Y, Kamino E et al.: WT1 IgG antibody for early detection of non-small cell lung cancer and as its prognostic factor. Int. J. Cancer125(2),381–387 (2009).Crossref, Medline, CAS, Google Scholar7 Tamura H, Dan K, Yokose N et al.: Prognostic significance of WT1 mRNA and anti-WT1 antibody levels in peripheral blood in patients with myelodysplastic syndromes. Leuk. Res.34(8),986–990 (2010).Crossref, Medline, CAS, Google Scholar8 Scheibenbogen C, Letsch A, Thiel E et al.: CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood100(6),2132–2137 (2002).Crossref, Medline, CAS, Google Scholar9 Rezvani K, Grube N, Brenchley JM et al.: Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood102(8),2892–2900 (2003).Crossref, Medline, CAS, Google Scholar10 Oka Y, Tsuboi A, Murakami M et al.: Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int. J. Hematol.78(1),56–61 (2003).Crossref, Medline, CAS, Google Scholar11 Oka Y, Tsuboi A, Taguchi T et al.: Induction of WT1 (Wilms' tumor gene)-specific T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc. Natl Acad. Sci. USA101(38),13885–13890 (2004).Crossref, Medline, CAS, Google Scholar12 Rezvani K, Yong AS, Mielke S et al.: Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood111(1),236–22 (2008).Crossref, Medline, CAS, Google Scholar13 Keilholz U, Letsch A, Busse A et al.: A clinical and immunological Phase II trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with MDS and AML. Blood113(26),6541–6548 (2009).Crossref, Medline, CAS, Google Scholar14 Narita M, Masuko M, Kurasaki T et al.: WT1 peptide vaccination in combination with imatinib therapy for a patient with CML in the chronic phase. Int. J. Med. Sci7(2),72–81 (2010).Crossref, Medline, CAS, Google Scholar15 Ohno S, Kyo S, Myojo S et al.: Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy. Anticancer Res.29(11),4779–4784 (2009).Medline, CAS, Google Scholar16 Izumoto S, Tsuboi A, Oka Y et al: Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma. J. Neurosurg.108(5),963–971 (2008).Crossref, Medline, CAS, Google Scholar17 Hashii Y, Sato E, Ohta H et al.: WT1 peptide vaccination for cancer in children and young adults. Pediat. Blood Cancer26(1),74–83 (2010).Google Scholar18 Iiyama T, Udaka K, Takeda S et al.: WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinoma. Microbiol. Immunol.51(5),519–530 (2007).Crossref, Medline, CAS, Google Scholar19 Oka Y, Elisseeva OA, Tsuboi A et al.: Human cytotoxic T lymphocyte responses specific for peptides of wild-type Wilms' tumor gene (WT1) product. Immunogenetics51(2),99–107 (2000).Crossref, Medline, CAS, Google Scholar20 Gao L, Bellantuono I, Elsasser A et al.: Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood95(7),2198–2203 (2000).Crossref, Medline, CAS, Google Scholar21 Ohminami H, Yaswukawa M, Fujita S: HLA class I-restricted lysis of leukemic cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood95(7),2198–2203 (2000).Crossref, Medline, Google Scholar22 Oka Y, Udaka K, Tsuboi A et al.: Cancer immunotherapy targeting Wilms' tumor gene WT1 product. J. Immunol.164(4),1873–1880 (2000).Crossref, Medline, CAS, Google Scholar23 Bocchia M, Gentili S, Abruzzese E et al.: Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukemia and persistent residual disease: a multicentre observational trial. Lancet365(9460),657–662 (2005).Crossref, Medline, CAS, Google Scholar24 Van Tendeloo VF, Van de Velde A, Van Driessche A et al.: Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc. Natl Acad. Sci. USA107(31),13824–13829 (2010).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByA case of long-term complete response obtained by combination therapy with anticancer drugs and a dendric cell vaccine for gastric cancer with multiple liver metastasisProgress of Digestive Endoscopy, Vol. 95, No. 1A new peptide vaccine OCV-501: in vitro pharmacology and phase 1 study in patients with acute myeloid leukemia20 March 2017 | Cancer Immunology, Immunotherapy, Vol. 66, No. 7The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapyEndocrine-Related Cancer, Vol. 24, No. 4WT1 Peptide Vaccine for the Treatment of Malignancies: Its Development, Recent Progress, and Future Perspectives23 February 2016Dendritic cell-based cancer immunotherapy for colorectal cancerWorld Journal of Gastroenterology, Vol. 22, No. 17Association of Wilms' tumor 1 gene single-nucleotide polymorphism rs16754 with colorectal cancer16 September 2015 | Molecular and Clinical Oncology, Vol. 3, No. 6Enhancement of Efficacy of Wilms' Tumor Gene WT1 Product-derived Peptide Cancer Vaccine by Co-administration with Immunopotentiating Agents: Lessons from Mouse ModelsA vaccine for leukemia: one step closer? Cure-oriented WT1 peptide vaccination therapy is being developedClinical Investigation, Vol. 3, No. 5WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial18 November 2012 | Journal of Cancer Research and Clinical Oncology, Vol. 139, No. 3Novel and Emerging Therapies Safeguarding Health of Humans and Their Companion Animals: A ReviewPakistan Journal of Biological Sciences, Vol. 16, No. 3Novel report of expression and function of CD97 in malignant gliomas: correlation with Wilms tumor 1 expression and glioma cell invasivenessJournal of Neurosurgery, Vol. 116, No. 4Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia26 April 2011 | Cancer Immunology, Immunotherapy, Vol. 60, No. 6The cyclins: a family of widely expressed tumor antigens?9 January 2014 | Expert Review of Vaccines, Vol. 10, No. 3Adoptive T-cell immunotherapy using T-cell receptor gene transfer: aiming at a cure for cancerMasaki Yasukawa, Toshiki Ochi & Hiroshi Fujiwara15 February 2011 | Immunotherapy, Vol. 3, No. 2 Vol. 2, No. 5 Follow us on social media for the latest updates Metrics History Published online 29 September 2010 Published in print September 2010 Information© Future Medicine LtdKeywordscancer antigenpeptide vaccineWT1Financial & competing interests disclosureThis work is supported by a Grant-in-Aid from the Ministry of Education, Science, Sports, Culture and Technology, Japan. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. The authors used Nakamura Systems Colt. (Ikeda City, Japan) for English writing assistance in the production of this manuscript.PDF download